ClinicalTrials.gg
Status unknownNCT05173467Updated Dec 30, 2021

Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor

An interventional study of Robot-assisted Invasion-controlled Surgery and Traditional-open Surgery in Minimally Invasive Surgery and Spinal Metastases, sponsored by Wei Xu. Status unknown at 1 site in China. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2021-12-30.

Sponsored by Wei Xu · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

With significant advances in diagnostic imaging and systemic therapies for oncologic disease, spinal metastasis with neurological dysfunction and mechanical instability has become an indication for surgery. Even if traditional-open surgery was palliative, the treatment of spinal metastasis also carried significant surgical morbidity. Those high morbidity and complication rates may influence the quality of patients with a limited life expectancy. Invasion-controlled surgery was utilized with Robot-assisted surgery approach against symptomatic spinal metastasis.

Increasing interest in the potential for improved consistency, complication reduction, and decreased length of hospitalization through robot utilization is evident from the rapid growth of publications seen in recent years.

So, the investigators wish to evaluate the advantages of Robot-assisted Invasion-controlled Surgery compared with traditional-open surgery spinal surgery in patients with metastatic spinal cord compression.

Read the detailed description

Surgical Spinal Decompression of Metastatic Spinal Cord Compression, Minimal Access Versus Open Surgery. A prospective Clinical Trial

Purpose To investigate the effect of Robot-assisted Invasion-controlled Surgery compared with traditional-open surgery in the treatment of patients with metastatic spinalcord compression.

Hypotheses The group of patient's receiving robot-assisted invasion-controlled surgery will have better improvement in quality after surgery compared to the group that will receive traditional open surgery. The robot-assisted invasion-controlled surgery group will have reduction in per-operative bleeding and less wound complications compered to the group of patients receiving open or traditional surgery.

02

Conditions studied

  • Minimally Invasive Surgery
  • Spinal Metastases

Browse trials for

Keywords

  • Minimal surgery
  • Spinal Metastases
  • invsasion-controlled surgery
  • traditional-open surgery
  • Robot-assisted
03

In context

Neoplasm Metastasis

4,040 studies on the registry are indexed under Neoplasm Metastasis; 886 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 3,268 interventional studies indexed under Neoplasm Metastasis.

Browse Neoplasm Metastasis studies →

Lead sponsor

Wei Xu is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of spinal (previously confirmed diagnosis of lung cancer, liver cancer, prostate cancer, breast cancer, kidney cancer, digestive tract cancer, imaging indicated the presence of metastatic lesions in the spine)
  2. Patients with symptoms of spinal instability or nerve compression (SINS score of spinal instability ≥7, spinal nerve compression according to spinal cord injury Classification, grade A-D)
  3. Metastases are located in the thoracic and/or lumbar vertebrae
  4. The patient's expected survival was longer than 6 months
  5. The subjects or their legal representatives were able to understand the study purpose, demonstrate adequate compliance with the study protocol, and sign

Exclusion criteria

Exclusion Criteria:

  1. He had previously operated on the same site
  2. Spontaneous multiple compression fractures of the spine;
  3. There is malformed osteitis (Paget's bone disease), osteomalacia, or other metabolic bone disease;
  4. here were developmental vertebral malformations or vertebral body and pedicle dysplasia in the spinal segment to be treated by surgery
  5. Presence of heart, lung, liver or kidney failure or other serious diseases (such as osteomyelitis, systemic infection, severe hemorrhagic disease, active disseminated intravascular coagulation, serious cardiovascular disease or myocardial infarction within 6 months prior to enrollment, cerebral infarction within 6 months prior to enrollment, severe psychiatric history)
  6. Pregnant or lactating women
  7. Participated in clinical trials of other drugs or medical devices within 3 months prior to enrollment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Robot-assisted Invasion-controlled Surgery

    Procedure: Robot-assisted Invasion-controlled Surgery

  • Placebo comparator
    Traditional-open Surgery

    Procedure: Traditional-open Surgery

Interventions

  • ProcedureRobot-assisted Invasion-controlled Surgery

    The concept of invasion-controlled surgery (ICS) for spinal metastasis has been put forward against the spinal instability and neurological dysfunction of frail patients that might not allowed for radical traditional open surgery including improvements of multidisciplinary dynamic assessments, endovascular detachable balloon embolization, minimal-invasion by using expandable working tubes, percutaneous pedicle screws, and some accurate therapy. ICS could provide immediate stability, deformity correction, and recovery of neurological function.

  • ProcedureTraditional-open Surgery

    This traditionally requires a midline incision, bilateral muscle strip, and multilevel laminectomy to provide adequate access and safe removal of the tumor.

06

What researchers measure

Primary outcomes

  1. operative bleeding

    It is amount of blood lost during surgery, which is checked by the anesthesiologist and the surgical nurse.

    Time frame: Intraoperative

Secondary outcomes

  1. operation time

    Is the time from the beginning of the operation to the end of the incision suture is the total operation time

    Time frame: Intraoperative

  2. Intraoperative transfusion volume

    That is the amount of intraoperative red blood cell suspension and plasma input and the incidence of blood transfusion.

    Time frame: Intraoperative

  3. Intraoperative fluoroscopy dose

    The product of intraoperative c-arm fluoroscopy times and single fluoroscopy dose

    Time frame: Intraoperative

  4. VAS Scores

    It isrecorded at1D-3D after surgery (morning, middle and evening assessment every day, in which the most pain of each day was recorded. All patients were standardized to use the same dose of non-steroidal antipyretic and analgesic drugs; if temporary addition of A tablet analgesics was needed, VAS score before use was recorded and the dosage of A tablet was recorded), 2W after surgery, And 3M (long-term postoperative pain)

    Time frame: less than 2 years

  5. Frankel Scores

    The Frankel Scale for Spinal Cord Injury That Classifies the Extent of the Neurological/Functional Deficit into Five Grades

    Time frame: less than 2 years

  6. Creatine kinase levels

    reatine kinase were examined 1 day after operation

    Time frame: less than 2 years

  7. myoglobin

    myoglobin were examined 1 day after operation

    Time frame: less than 2 years

  8. Complications

    Postoperative wound complications were observed during the hospital period, including the incidence of wound infection, wound nonunion, wound debridement, and the frequency of massive bleeding, lung infection, urinary tract infection and other complications

    Time frame: less than 2 years

  9. QOL Scores

    Quality of life (QOL) is a multidimensional concept that measures a person's wellbeing.

    Time frame: less than 2 years

  10. resuming time of daily life

    Time spent in bed after surgery was recorded

    Time frame: less than 2 years

  11. Survival time

    Survival time

    Time frame: less than 2 years

  12. ODI scores

    The ODI is comprised of 10 questions. The questionnaire asks patients about their ability to manage everyday life and covers intensity of pain, lifting, the ability to care for oneself, ability to walk, the ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel. Answers are then scored on a 0-5 scale, zero meaning no disability.

    Time frame: less than 2 years

07

Study locations

1 site
  • ChangZheng Hospital
    Shanghai, Shanghai 200001, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05173467
Lead sponsor
Wei Xu
Responsible party
Wei Xu (Clinical Professor, Shanghai Changzheng Hospital) — Sponsor-investigator
First posted
Dec 30, 2021
Start date
Dec 25, 2021 (estimated)
Primary completion
Dec 10, 2022 (estimated)
Completion
Dec 10, 2023 (estimated)
Last update
Dec 30, 2021

Study contacts

wei Xu, profession
Contact
xuweichangzheng@hotmail.com
13761278657 ext. 86-21-81885045
Jianru Xiao, Profession
study chair · Shanghai Changzheng Hospital
Wei Xu, Profession
study director · Shanghai Changzheng Hospital
Bo Li, Profession
principal investigator · Shanghai Changzheng Hospital
Pengru Wang, Profession
principal investigator · Shanghai Changzheng Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion